We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FTC last week granted conditional approval of Johnson & Johnson's (J&J) proposed $25.4 billion purchase of Guidant, but J&J indicated it might scuttle the deal in light of Guidant's recent product recalls and regulatory investigations.
After being spurned by Chiron six weeks ago, Novartis has agreed to pay $5.1 billion to acquire full control of the California-based drugmaker — a move that significantly boosts its presence in the red-hot vaccines market.
Iceland-based drugmaker Actavis has taken another major step to expand its presence in the generics market, announcing that it plans to purchase Alpharma's U.S. and international generics businesses for roughly $810 million.
After being spurned by Chiron six weeks ago, Novartis has agreed to pay $5.1 billion to acquire full control of the California-based drugmaker -- a move that significantly boosts its presence in the red-hot vaccines market.
Johnson & Johnson (J&J) reportedly wants to renegotiate a lower purchase price for Guidant — a possibility that prompted a response from Guidant defending the original deal.
In what analysts are calling a positive resolution for Wyeth, the firm has settled its patent dispute with Teva Pharmaceutical over its blockbuster antidepressant and anxiety drug Effexor.
Iceland-based drugmaker Actavis has taken another major step to expand its presence in the generics market, announcing Oct. 17 that it plans to purchase Alpharma’s U.S. and international generics businesses for roughly $810 million.
Teva Pharmaceutical and Ivax will probably not have to sell off many products to consummate their pending merger, a Standard & Poor’s analyst said, despite an FTC request for more information about the proposed deal.
Rumors that the FDA may be launching a criminal investigation into how Guidant handled flaws with its implantable heart devices could delay Johnson & Johnson’s (J&J) purchase of the device manufacturer, according to industry analysts.
Bristol-Myers Squibb (BMS) is combining its U.S. and international pharmaceutical operations — one of several organizational shake-ups announced Sept. 20 by the New York-based firm.